Monte Rosa Therapeutics, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. The unaudited financial statements are prepared under U.S. GAAP. Monte Rosa is a clinical-stage biotechnology company developing small-molecule molecular glue degraders using its QuEEN platform; it reported no product revenue.
Financial results and position
| Metric | Q1 2022 | Q1 2021 / prior date |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $17.9 million | $9.3 million |
| General and administrative expense | $6.4 million | $2.2 million |
| Total operating expenses / operating loss | $24.3 million | $11.5 million |
| Net loss | $23.9 million | $12.3 million |
| Net loss per share, basic and diluted | $0.51 | $7.18 |
| Net cash used in operating activities | $27.4 million | $13.8 million |
| Cash, cash equivalents and marketable securities | $317.2 million | $346.1 million cash and equivalents at December 31, 2021; no marketable securities reported then |
At March 31, 2022, cash, cash equivalents and restricted cash totaled $143.6 million; marketable securities were $178.9 million. Total assets were $346.0 million, total liabilities $20.1 million, and stockholders’ equity $325.9 million. The company reported no debt or credit facility and stated it had no committed sources of capital. Its accumulated deficit was $146.0 million.
Operating expenses rose $12.8 million year over year. R&D increased $8.6 million, primarily with higher external research costs, personnel, facilities and laboratory spending as operations expanded. G&A increased $4.2 million, reflecting headcount, professional services and other costs supporting growth and public-company operations. No meaningful operating margin is presented because the company has no product revenue.
Cash flows, liquidity and commitments
- Operating cash use was $27.4 million, up from $13.8 million a year earlier. Investing cash use was $180.5 million, mainly $179.0 million of marketable-security purchases and approximately $1.7 million of property and equipment purchases. Financing provided $0.2 million, primarily from employee option exercises.
- Cash, cash equivalents and restricted cash declined $207.8 million during the quarter. The large investing outflow largely reflects moving funds into marketable securities, rather than operating expenditure.
- Management said cash, cash equivalents and marketable securities, excluding restricted cash, were expected to fund operating expenses and capital needs for at least 12 months from issuance of the financial statements. It expects continued losses and cash use and says additional funding will be needed for future research and development.
- Operating lease liabilities totaled $7.0 million at quarter-end. A separate 63,327-square-foot office and laboratory lease commenced April 1, 2022, with a 128-month initial term; rent is scheduled to begin no later than December 1, 2022. Estimated future payments include $44.4 million thereafter. These obligations were not included in the March 31 balance sheet because the lease had not commenced.
Business outlook, risks and notable items
- The company identified a planned FDA IND submission for a GSPT1-directed molecule in the first half of 2022, followed, if permitted, by initiation of a clinical trial. It also described continued preclinical work across GSPT1, NEK7, CDK2, VAV1 and BCL11A programs, and advancement of MRT-2359. These are plans, not assurances of timing or success.
- Management expects R&D, G&A and capital expenditures to increase as programs advance, clinical and manufacturing work expands, and facilities and staffing grow. The company has no approved products and cannot predict when, if ever, it will generate significant product revenue or become profitable.
- Funding needs depend on development progress, trial and manufacturing costs, regulatory timing, hiring, collaborations and other factors. If financing is unavailable on acceptable terms, the company may need to delay, reduce or end programs. Equity financing could dilute shareholders; debt could impose restrictive covenants.
- COVID-19 had not significantly affected operations to date, and vendors were not then anticipating supply or service disruptions. Future effects remained uncertain.
- On May 5, 2022, the company entered an agreement giving it an option, subject to the landlord leasing to a new tenant, to terminate its 645 Summer Street lease by notice during February 1–June 1, 2023. The current lease otherwise expires in March 2026.
- Disclosure controls and procedures were reported ineffective at March 31, 2022. Previously identified material weaknesses in staffing, risk assessment, control activities, segregation of duties and documentation had not been remediated. Remediation efforts were ongoing.
- The company reported no legal proceeding expected to have a material adverse effect and no material change to most risk factors from its 2021 Form 10-K. Marketable securities had $0.2 million of aggregate unrealized losses; management attributed these primarily to market conditions and did not expect to sell the securities before recovery.
Most important facts for investors to verify
- Whether the planned first-half 2022 GSPT1 IND submission occurred, and the timing, regulatory status and clinical progress of MRT-2359 and other programs.
- Cash burn and the composition and liquidity of cash, cash equivalents and marketable securities; assess runway against the stated 12-month estimate and planned spending increases.
- The cost and timing of the new laboratory lease, rent commencement, and any outcome of the conditional 645 Summer Street lease termination option.
- Progress in remediating the material weaknesses and whether disclosure controls and internal controls are subsequently assessed as effective.
- Potential financing requirements and dilution, as well as milestones, manufacturing, clinical and regulatory risks that could change spending or program timelines.